Eli Lilly and Company (LLY) Q1 2026 (USD): Adj. EPS 8.55 (exp. 6.88), Revenue 19.8bln (exp. 17.68bln), Mounjaro 8.66bln, Zepbound 4.16bln
Guidance:
- FY adj. EPS 35.50-37 (exp. 34.52).
- FY revenue 82-85bln (exp. 82.1bln).
Context
Eli Lilly's strong Q1 results, with an adjusted EPS and revenue significantly beating expectations, indicate robust performance driven by key products like Mounjaro and Zepbound. This outperformance, coupled with positive full-year guidance, suggests strong momentum in the pharmaceutical sector, which may bolster investor sentiment towards the stock. Traders should consider potential upward revisions in earnings expectations and implications for sector peers.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#ELI LILLY & CO#LLY.US#IMPORTANT#FOREX#EQUITIES#METALS#EU SESSION#PHARMACEUTICALS#METALS & MINING#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#DXY#US EQUITIES